Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. According to the filing, all 45,867 option shares will vest 100% on the first anniversary of the grant date, if she continues in service through that vesting date. Following this grant, she holds 45,867 stock options directly.
Pyxis Oncology director Darren S. Cline received a stock option grant for 45,867 shares of Common Stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. All 45,867 option shares vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Cline holds options covering 45,867 shares, and the filing shows no same-day exercises or market purchases or sales.
Pyxis Oncology, Inc. director Rachel Humphrey received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and were awarded at no cost to her.
The filing states that all 45,867 options will vest 100% on the first anniversary of the March 24, 2026 grant date, as long as she continues in service through that date. Following this award, her reported derivative holdings from this grant total 45,867 stock options.
Pyxis Oncology, Inc. director Palani Santhosh received a grant of stock options covering 45,867 shares of common stock. The options carry an exercise price of $1.36 per share and expire on March 24, 2036. All 45,867 options will vest 100% on the first anniversary of the grant date, conditioned on his continued service through that vesting date. Following this grant, he holds 45,867 stock options directly.
Pyxis Oncology director Rachel Humphrey reported open-market sales of a total of 15,496 shares of Pyxis Oncology common stock. The sales occurred on April 14, 17, and 21, 2025 at prices of $0.9727, $0.97, and $1.0335 per share, respectively.
The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2024, indicating they were pre-scheduled. Following the latest sale, Humphrey directly holds 81,309 shares of Pyxis Oncology common stock.
Pyxis Oncology is a clinical-stage cancer company focused on its lead antibody-drug conjugate MICVO for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO targets the EDB+FN splice variant in the tumor microenvironment to deliver an auristatin payload via a three-pronged mechanism of direct killing, bystander effect and immune activation.
Phase 1 monotherapy data in heavily pretreated 2L+ R/M HNSCC at 5.4 mg/kg every three weeks showed a confirmed objective response rate of 46% and disease control in 92% of evaluable patients, with manageable but notable Grade ≥3 treatment-related adverse events, especially in higher body-weight patients. Pyxis is implementing dose caps and adjusted ideal body weight dosing to improve tolerability.
MICVO has Fast Track designation in 2L+ R/M HNSCC, and the company has obtained FDA feedback on a planned pivotal monotherapy trial. A Phase 1/2 combination study with pembrolizumab in 1L/2L+ R/M HNSCC reported a 71% confirmed response rate and 100% disease control in early data, with no Grade 3/4 ADC payload toxicities. Updated monotherapy data are expected mid-2026 and additional combination data in the second half of 2026, while several earlier programs are paused and available for partnering.
Pyxis Oncology reported a full-year 2025 net loss of $79.6 million, or ($1.28) per share, on total revenues of $13.9 million, primarily from suvemcitug milestones and the sale of Enzeshu royalty rights. Research and development expenses rose to $73.7 million, driven by MICVO monotherapy and combination trials.
As of December 31, 2025, the company held $68.3 million in cash, cash equivalents, restricted cash and short-term investments and expects its cash runway to extend into the fourth quarter of 2026. MICVO showed a 46% confirmed objective response rate and 92% disease control rate as monotherapy in 2L+ recurrent/metastatic head and neck cancer, and a 71% confirmed response rate in combination with KEYTRUDA in early data.
Pyxis completed target enrollment in its Phase 1 monotherapy dose expansion study in 2L+ head and neck cancer in the first quarter of 2026, with updated monotherapy data expected mid‑2026 and updated combination data in the second half of 2026. The company also strengthened leadership, appointing Thomas Civik as Interim CEO and adding senior clinical, program and investor relations executives.
Laurion Capital Management LP and related individuals report a significant ownership stake in Pyxis Oncology, Inc. They disclose beneficial ownership of 4,796,479 shares of Pyxis Oncology common stock, representing 7.72% of the class as of 12/31/2025.
Laurion Capital, along with Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, report shared voting and shared dispositive power over all of these shares and no sole power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pyxis Oncology.
Pyxis Oncology, Inc. announced a leadership transition in which Lara S. Sullivan, M.D. ceased serving as Chief Executive Officer and principal executive officer effective February 2, 2026. The Board appointed director Thomas (Tom) Civik as Interim Chief Executive Officer and principal executive officer, effective the same date.
Under an interim employment agreement, Mr. Civik will receive an annualized base salary of $710,000 and be eligible for a target bonus equal to 60% of that salary, prorated for his service. Subject to Board approval, he will receive stock options for 1.1% of outstanding common stock vesting in 12 equal monthly installments during his interim term, and an additional fully vested option for 0.4% of outstanding common stock upon completion of a successful financing or strategic transaction during the interim term or within six months after.
A concurrent press release highlights the Board’s ongoing search for a permanent CEO and emphasizes continuity for Pyxis Oncology’s lead antibody-drug conjugate, micvotabart pelidotin (MICVO), which is being evaluated in Phase 1 and Phase 1/2 clinical studies in recurrent/metastatic head and neck squamous cell carcinoma and other solid tumors.
Pyxis Oncology, Inc. reported that Interim Chief Executive Officer and director Thomas Civik received a new stock option grant. On February 3, 2026, he was awarded an option to purchase 690,131 shares of common stock at an exercise price of $1.49 per share, expiring on February 3, 2036.
The option vests in 12 equal monthly installments, starting on the grant date, and each monthly vesting is conditioned on his continued service as Interim Chief Executive Officer through the applicable vesting date. Following this grant, he beneficially owns 690,131 derivative securities directly in the form of this option.